Japan's Senju Pharmaceutical has licensed U.S.-based Eyenovia's portfolio of microdosed ophthalmic treatments to develop and market throughout Asia. Financial arrangements were not disclosed, but the global market for such drugs is $19 billion.
As part of the agreement, Senju agreed to join an investment syndicate with three venture companies and cover its own research and development costs in Asia.
Eyenovia has developed clinical-stage microdosing technology and markets it as significantly improving bioavailability, efficacy and safety of existing eye drugs without requiring chemical reformulation.
- here's the release